TELA Bio Q3 2023 EPS $(0.45) Beats $(0.49) Estimate, Sales $15.05M Miss $16.20M Estimate
Portfolio Pulse from totan@benzinga.com
TELA Bio reported Q3 2023 earnings per share (EPS) of $(0.45), beating the analyst consensus estimate of $(0.49) by 8.16%. However, the company's quarterly sales of $15.05 million missed the analyst consensus estimate of $16.20 million by 7.09%. Despite the miss, this represents a 34.89% increase over sales from the same period last year.
November 09, 2023 | 9:26 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
TELA Bio's Q3 2023 earnings beat estimates but sales missed. The EPS of $(0.45) beat estimates by 8.16%, while sales of $15.05 million missed estimates by 7.09%.
TELA Bio's mixed Q3 2023 results, with earnings beating estimates but sales missing, could lead to neutral short-term price movement. Investors may react positively to the earnings beat, but negatively to the sales miss.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100